ONCO
Onconetix, Inc. (NASDAQ)
Healthcare — Biotechnology
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Price History
Fundamentals
| Market Cap | $3.99M |
| P/E Ratio (TTM) | 0.00 |
| Forward P/E | -1.27 |
| EPS (TTM) | $1377.40 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -78.90% |
| ROE | -123.28% |
| Debt/Equity | 2.47 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 51.9 |
| Beta | 2.72 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $270.00 |
| 52-Week Low | $0.88 |
| 50-Day Avg | $2.83 |
| 200-Day Avg | $70.75 |
| Avg Volume | $1.07M |
| Volume | 136.3K |
Performance Analysis
NEUTRALONCO presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:24 UTC
Back to Screener Export Report